Home Drug IndexClinical Monograph

Low Molecular Weight Heparin (LMWH) Uses, Dosage, Side Effects | DrugsAtlas

Authoritative Clinical Reference

Therapeutic Class

Anticoagulant

Subclass

Low Molecular Weight Heparin (Factor Xa inhibitor predominant)

Speciality

Haematology

Schedule (India)

Schedule H

Routes

Subcutaneous (SC), Intravenous (IV — limited indications, e.g., PCI)

Formulations

Enoxaparin: 20 mg/0.2 mL, 40 mg/0.4 mL, 60 mg/0.6 mL, 80 mg/0.8 mL, 100 mg/1 mL prefilled syringes
Dalteparin: 2,500 IU/0.2 mL, 5,000 IU/0.2 mL, 7,500 IU/0.3 mL prefilled syringes
Nadroparin: 2,850 IU/0.3 mL, 5,700 IU/0.6 mL prefilled syringes
Tinzaparin: NOT AVAILABLE in India
Certoparin: NOT AVAILABLE in India
Reviparin: NOT AVAILABLE in India

Adult indications

INDICATIONS + DOSING — FOR CLINICIAN USE ONLY

Primary Indications (Approved / Standard in India)

Note: Enoxaparin is the most widely available and studied LMWH in India. Dosing below refers primarily to Enoxaparin unless otherwise specified.

1. Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE)

Parameter	Recommendation
Starting dose	1 mg/kg SC every 12 hours OR 1.5 mg/kg SC once daily
Titration	Not routinely required; adjust based on anti-Xa levels in special populations
Usual maintenance dose	1 mg/kg SC every 12 hours
Maximum dose	Weight-based; dose-cap in obesity (consider max 100 mg per dose in morbid obesity)

Clinical Notes:

Duration: 5–10 days; overlap with oral anticoagulant (warfarin) until INR ≥2 for at least 24 hours
Transition to DOAC (rivaroxaban, apixaban) may be considered after initial treatment
Monitor platelet count for HIT surveillance
Once-daily dosing (1.5 mg/kg) may be preferred for outpatient management

2. Prophylaxis of Venous Thromboembolism (VTE) in High-Risk Patients

(Post-operative, immobilised medical patients, critically ill)

Parameter	Recommendation
Starting dose	40 mg SC once daily (Enoxaparin)
Titration	Not applicable
Usual maintenance dose	40 mg SC once daily
Maximum dose	40 mg/day for standard prophylaxis

Clinical Notes:

Initiate 6–12 hours post-surgery once haemostasis is secured
Duration: 7–14 days for general surgery; extend up to 35 days for major orthopaedic surgery (hip/knee replacement)
Reduce to 20 mg SC once daily in patients with body weight <45 kg or high bleeding risk
For medical patients, continue until patient is ambulatory

Alternative LMWH Dosing for VTE Prophylaxis:

LMWH	Prophylactic Dose
Dalteparin	2,500–5,000 IU SC once daily
Nadroparin	2,850 IU SC once daily (weight-adjusted in higher risk)

3. Acute Coronary Syndromes (Unstable Angina / NSTEMI)

Parameter	Recommendation
Starting dose	1 mg/kg SC every 12 hours
Titration	Not applicable
Usual maintenance dose	1 mg/kg SC every 12 hours
Maximum dose	No fixed ceiling; assess renal function and bleeding risk

Clinical Notes:

Duration: 2–8 days or until revascularisation
Use in conjunction with dual antiplatelet therapy (aspirin + P2Y12 inhibitor)
Reduce dose in elderly ≥75 years: 0.75 mg/kg SC every 12 hours (no initial IV bolus)
In renal impairment (CrCl <30 mL/min): 1 mg/kg SC once daily

4. ST-Elevation Myocardial Infarction (STEMI) — With or Without Fibrinolysis

Age Group	Initial Dose	Maintenance Dose
<75 years	30 mg IV bolus, then 1 mg/kg SC (max 100 mg for first two doses)	1 mg/kg SC every 12 hours
≥75 years	No IV bolus	0.75 mg/kg SC every 12 hours (max 75 mg for first two doses)

Clinical Notes:

Duration: Until revascularisation or up to 8 days
Adjust dose in renal impairment
If PCI performed within 8 hours of last SC dose, no additional anticoagulation needed
If PCI performed 8–12 hours after last SC dose, give additional 0.3 mg/kg IV bolus

5. Anticoagulation During Pregnancy

(Mechanical heart valves, VTE treatment/prophylaxis, thrombophilia)

Parameter	Recommendation
Starting dose	1 mg/kg SC every 12 hours (therapeutic) OR 40 mg SC once daily (prophylactic)
Titration	Adjust based on anti-Xa levels (target: 0.5–1.0 IU/mL for therapeutic; 0.2–0.4 IU/mL for prophylactic)
Usual maintenance dose	Weight-based; reassess each trimester as weight changes
Maximum dose	Individualised based on anti-Xa monitoring

Clinical Notes:

Specialist initiation and monitoring mandatory
Monitor anti-Xa levels 4 hours post-dose, especially with mechanical valves
Discontinue 24 hours before planned delivery; switch to UFH if delivery imminent
Resume 6–12 hours post-delivery if no bleeding

Secondary Indications — Adults (Off-label, if any)

Indication	Dose	Duration	Label Status	Evidence Basis
Cancer-associated thrombosis (VTE treatment/secondary prophylaxis)	Enoxaparin 1 mg/kg SC every 12 hours	Up to 6 months	OFF-LABEL	AIIMS Oncology protocols; NCG Guidelines; CLOT trial
Post-COVID VTE prophylaxis (high-risk patients post-discharge)	Enoxaparin 40 mg SC once daily	2–4 weeks post-discharge	OFF-LABEL; Specialist only	Indian institutional protocols; AIIMS/ICMR guidance during pandemic
Bridging anticoagulation (peri-procedural for patients on warfarin)	Therapeutic: 1 mg/kg SC every 12 hours; Prophylactic: 40 mg SC once daily	Variable; until oral anticoagulation resumed	OFF-LABEL	Indian cardiology and haematology practice

Paediatric indications

PAEDIATRIC DOSING (Specialist Only)

Primary Indications (Approved / Standard in India)

Treatment of Venous Thromboembolism (DVT/PE), Arterial Thrombosis, Central Line-Associated Thrombosis

Note: Enoxaparin is the preferred LMWH for paediatric use in India per IAP and AIIMS protocols.

Preterm neonates	1.5–2 mg/kg every 12 hours	0.75 mg/kg every 12 hours	0.5–1.0 IU/mL (treatment)
Term neonates (<28 days)	1.5 mg/kg every 12 hours	0.75 mg/kg every 12 hours	0.5–1.0 IU/mL (treatment)
Infants (1–12 months)	1.5 mg/kg every 12 hours	0.75 mg/kg every 12 hours	0.5–1.0 IU/mL (treatment)
Children (1–5 years)	1.0 mg/kg every 12 hours	0.5 mg/kg every 12 hours	0.5–1.0 IU/mL (treatment)
Children (6–18 years)	1.0 mg/kg every 12 hours	0.5 mg/kg every 12 hours	0.5–1.0 IU/mL (treatment)

Titration:

Check anti-Xa level 4 hours after 3rd or 4th dose
Adjust dose by 10–25% increments to achieve target anti-Xa
Recheck anti-Xa after each dose adjustment

Safety Monitoring:

Baseline: CBC with platelet count, PT, aPTT, renal function, LFTs
Platelet count every 2–3 days for first 2 weeks
Anti-Xa levels mandatory for dose adjustment
Monitor for bleeding (injection sites, mucous membranes, intracranial in neonates)
Assess renal function periodically

Minimum Age: Use with caution in preterm neonates; specialist paediatric haematology supervision mandatory in neonates.

Secondary Indications — Paediatrics (Off-label, if any)

Indication	Dose	Duration	Label Status	Evidence Basis
Central venous catheter patency/thrombosis prophylaxis	0.5 mg/kg SC every 12–24 hours	Duration of catheter placement	OFF-LABEL; Specialist only	IAP protocols; Indian PICU practice
Post-cardiac surgery with cannulas/mechanical support	0.5 mg/kg SC every 12 hours	Until decannulation	OFF-LABEL; Specialist only	Paediatric cardiac surgery protocols
Kawasaki disease with coronary artery aneurysms	1 mg/kg SC every 12 hours	Until transition to oral anticoagulation	OFF-LABEL; Specialist only	Indian paediatric cardiology practice

Age Restriction: Not recommended in preterm neonates except under specialist paediatric haematology or neonatology supervision with anti-Xa monitoring capability.

Renal Adjustments

eGFR (mL/min/1.73 m²)	Treatment Dose	Prophylactic Dose
≥30	No adjustment required	No adjustment required
15–29	Enoxaparin 1 mg/kg SC once daily	Enoxaparin 20–30 mg SC once daily
<15 or haemodialysis	Avoid LMWH; prefer UFH	Avoid LMWH; prefer UFH

Clinical Notes:

Calculate creatinine clearance (Cockcroft-Gault) for accurate dosing decisions
Anti-Xa monitoring recommended if LMWH must be used in severe renal impairment
Dalteparin and Nadroparin also require dose reduction in renal impairment; specific guidance limited in Indian literature
UFH is preferred in severe renal dysfunction due to reversibility and non-renal clearance

Hepatic adjustment

Contraindications

Active major bleeding (gastrointestinal, intracranial, retroperitoneal)
History of heparin-induced thrombocytopenia (HIT) type II
Severe thrombocytopenia (platelet count <50,000/μL unless thrombotic emergency)
Hypersensitivity to heparin, LMWH, or porcine-derived products
Recent haemorrhagic stroke
Severe uncontrolled hypertension
Active bacterial endocarditis
Recent or planned lumbar puncture, spinal, or epidural anaesthesia within inadequate time window

Cautions

Recent major surgery, trauma, or invasive procedures
History of peptic ulcer disease or gastrointestinal bleeding
Spinal/epidural anaesthesia — strict timing protocols required (minimum 12 hours after prophylactic dose; 24 hours after therapeutic dose before procedure)
Elderly patients (≥75 years) — increased bleeding risk
Low body weight (<45 kg) — consider dose reduction
Obesity (>100 kg) — may need higher doses; consider anti-Xa monitoring
Uncontrolled hypertension
Diabetic retinopathy with haemorrhagic risk
Concurrent antiplatelet therapy
Renal impairment (CrCl <30 mL/min) — drug accumulation risk

Pregnancy

Parameter	Recommendation
Safety status	Safe in pregnancy; does not cross placenta; no teratogenic effects
Preferred use	LMWH is preferred anticoagulant in pregnancy over warfarin (teratogenic) and UFH (less convenient)
Indications	VTE treatment/prophylaxis, mechanical heart valves, thrombophilia, antiphospholipid syndrome
Monitoring	Anti-Xa levels (especially with mechanical valves); platelet count; signs of bleeding; monthly reassessment of weight for dose adjustment
Peripartum management	Stop 24 hours before planned delivery; switch to UFH near term if delivery timing uncertain

Lactation

Parameter	Recommendation
Compatibility	Compatible with breastfeeding
Drug levels in milk	Negligible to undetectable; high molecular weight prevents significant transfer
Preferred status	LMWH is preferred over warfarin in early postpartum period
Infant monitoring	No specific monitoring required; observe for general health

Elderly

Starting dose: Use standard weight-based dosing for treatment; standard prophylactic doses acceptable
Age ≥75 years with ACS/STEMI: Reduce dose to 0.75 mg/kg SC every 12 hours (no IV bolus)
Titration: Not routinely required; reassess renal function before and during therapy
Extra risks:
- Increased bleeding risk due to age-related vascular fragility
- Declining renal function — recalculate CrCl frequently
- Higher fall risk — assess and counsel
- Polypharmacy — review for drug interactions
- Increased sensitivity to anticoagulant effects
Monitoring: More frequent CBC, renal function assessment, and clinical bleeding surveillance

Major drug interactions

Interacting Drug/Class	Mechanism/Effect	Recommendation
Antiplatelet agents (aspirin, clopidogrel, prasugrel, ticagrelor)	Synergistic bleeding risk	Essential in ACS; monitor closely; avoid high-dose aspirin
Oral anticoagulants (warfarin, acenocoumarol)	Additive anticoagulation	Brief overlap during transition only; monitor INR
Direct oral anticoagulants (rivaroxaban, apixaban, dabigatran, edoxaban)	Excessive anticoagulation	Avoid concurrent use; sequential use per protocol
Thrombolytics (alteplase, streptokinase, tenecteplase)	Markedly increased haemorrhage risk	Use sequentially, not concurrently; follow protocol timing
GP IIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban)	Synergistic bleeding	Dose adjustments per PCI protocols
Dextran	Additive anticoagulant effect	Avoid combination

Moderate drug interactions

Interacting Drug/Class	Mechanism/Effect	Recommendation
NSAIDs (diclofenac, ibuprofen, naproxen)	Increased GI bleeding risk; platelet inhibition	Avoid if possible; use short course with monitoring
SSRIs/SNRIs (fluoxetine, sertraline, venlafaxine)	Impaired platelet function	Monitor for bleeding
Corticosteroids (prolonged use)	Increased GI bleeding risk	Monitor for GI symptoms
Cephalosporins with MTT side chain (cefoperazone, cefotetan)	Vitamin K antagonism; increased bleeding	Monitor coagulation
Antitubercular drugs (rifampicin)	May alter metabolism of oral anticoagulants during overlap	Monitor INR if transitioning to warfarin
Valproic acid	Platelet dysfunction	Monitor for bleeding

Common Adverse effects

Injection site pain, bruising, and haematoma (10–20%)
Minor bleeding (gingival bleeding, epistaxis, haematuria)
Mild thrombocytopenia (non-immune; within first 2 days)
Transient elevation of hepatic transaminases
Local skin irritation at injection site

Serious Adverse effects

Heparin-induced thrombocytopenia (HIT) type II: Immune-mediated; typically day 5–14; paradoxical thrombosis; requires immediate discontinuation and alternative anticoagulation (fondaparinux, argatroban)
Major haemorrhage: Intracranial, retroperitoneal, gastrointestinal — requires discontinuation; partial reversal with protamine sulfate (60–80% neutralisation)
Spinal/Epidural haematoma: Associated with neuraxial anaesthesia; can cause permanent paralysis; strict timing protocols essential
Skin necrosis at injection site: Rare
Osteoporosis: With prolonged use (>3 months); less common than with UFH
Hyperkalaemia: Due to aldosterone suppression; monitor potassium in prolonged use
Anaphylaxis: Rare hypersensitivity reaction

Monitoring requirements

Timing	Parameters
Baseline	CBC with platelet count, PT/aPTT, serum creatinine, LFTs
After initiation (first 2 weeks)	Platelet count every 2–3 days (HIT surveillance)
Anti-Xa monitoring (when indicated)	4 hours post-dose; in pregnancy, obesity, extremes of weight, renal impairment, paediatrics
Long-term use	Periodic CBC, renal function; bone density if use >3 months
Clinical	Daily assessment for bleeding, injection site complications

Anti-Xa Target Levels:

Indication	Target Anti-Xa (IU/mL) — 4 hours post-dose
Therapeutic (twice daily dosing)	0.5–1.0
Therapeutic (once daily dosing)	1.0–2.0
Prophylactic	0.2–0.4

Brands in India

Enoxaparin:

Clexane® (Sanofi)
Lonopin® (Abbott)
Enclex® (Cipla)
Lupenox® (Lupin)
Enoxaparin Injection IP (Alkem, Intas, Glenmark, multiple generics)

Dalteparin:

Fragmin® (Pfizer)

Nadroparin:

Fraxiparine® (Aspen)

Note: Multiple generic enoxaparin formulations available; confirm dosage equivalence and bioequivalence before switching brands. LMWHs are not interchangeable with each other.

Price range (INR)

Formulation	Approximate Price	Notes
Enoxaparin 40 mg prefilled syringe	₹250–600 per syringe	Wide variation across brands
Enoxaparin 60 mg prefilled syringe	₹350–800 per syringe
Dalteparin 5,000 IU	₹400–800 per syringe	Limited availability
Nadroparin 2,850 IU	₹350–550 per syringe	Limited availability

NLEM Status: Enoxaparin (6,000 IU injection) is included in NLEM 2022; NPPA price-controlled for ceiling prices.

Government Supply: Available through government hospitals and NHM procurement.

Clinical pearls

Enoxaparin is the most widely available and best-studied LMWH in India; use it as the default choice unless specific indications favour alternatives
LMWHs are not interchangeable — do not switch between enoxaparin, dalteparin, and nadroparin during a treatment course
Anti-Xa monitoring is not routine but essential in: pregnancy (especially mechanical valves), extremes of body weight, renal impairment, paediatrics, and when therapeutic efficacy is uncertain
Always calculate creatinine clearance before initiating LMWH, especially in elderly patients — even "normal" serum creatinine may mask significant renal impairment
Strict timing protocols must be followed for neuraxial procedures: minimum 12 hours after prophylactic dose, 24 hours after therapeutic dose; reinitiate 4–6 hours after catheter removal
Protamine sulfate provides only partial reversal (60–80%) of LMWH; in life-threatening bleeding, give protamine 1 mg per 1 mg enoxaparin (if given within 8 hours); consider anti-Xa levels and additional supportive measures

Version

RxIndia v1.0 — 29 May 2025

Reference

- CDSCO product information
- Indian Pharmacopoeia / National Formulary of India
- NLEM 2022
- AIIMS Drug Formulary and Anticoagulation Guidelines
- API Textbook of Medicine
- IAP Guidelines for Paediatric Thrombosis Management
- ICMR/National Guidelines for Management of VTE
- Cardiological Society of India (CSI) ACS Management Guidelines
- NCG Guidelines for Cancer-Associated Thrombosis
- Indian Society of Haematology and Blood Transfusion (ISHBT) protocols

⚖️

Clinical Responsibility

This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.

Content Feedback

Is this information helpful?

Help us improve our clinical database for the medical community.

RxIndia

Loading clinical data...